Prague 2012 Programme Hotels Exhibition Visa Information Satellite Meetings
Back to Freepaper Session

Increase in distance corrected near visual acuity (DCNVA) over time after scleral spacing procedure (SSP) with PMMA implants for presbyopia

Session Details

Session Title: Refractive II

Session Date/Time: Saturday 04/02/2012 | 08:30-11:00

Paper Time: 08:42

Venue: Grand Ballroom

First Author: : B.Soloway UNITED STATES

Co Author(s): :                  

Abstract Details

Purpose:

To evaluate the DCNVA improvement with SSP and PMMA implants (PresView Scleral Implants: PSI, Refocus Group, Dallas, TX) at 3, 12 and 24 months post-op in emmetropic presbyopes

Setting:

FDA monitored Investigational Device Exemption (IDE) sites in the United States in Beverly Hills, CA; Buffalo, NY; Nashville, TN, New York, NY; and San Antonio, TX

Methods:

A prospective study was performed which measured DCNVA monocularly and binocularly under standardized mesopic illumination pre-operatively and at 3, 12, and 24 months post-operative successful SSP with PSI on 95 eyes of 52 consecutive patients in the USA FDA monitored IDE study. Patient inclusion criteria required 20/20 distance corrected visual acuity (DCVA), manifest refraction spherical equivalent between +0.75D, with1.00D or less astigmatism, and 20/62 or worse DCNVA. Patients were encouraged to aggressively use artificial tears and to increase illumination in favor of using glasses when reading in the early post-op time frame. Results at these time intervals were then compared. RESULTS Pre-op mean DCNVA was 20/74 ranging from 20/62 to 20/160. Post operatively 54%, 78%, and 100% of the eyes read 20/40 or better monocular DCNVA at 3, 12, and 24 months respectively. Binocular DCNVA of 20/40 or better was achieved with 83%, 94% and 100% of the patients at the same time intervals

Conclusions:

The improvements in DCNVA with SSP improve over time. Patients had better DCNVA when both eyes underwent SSP and were measured together

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented